Physician profile
Randall M Webb
NPI 1275560708
$30,748.57
in general payments reported to CMS, 2019-2025
72 companies · $7,134 in 2025
The $7,134 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,251 · 2020: $891 · 2021: $624 · 2022: $4,227 · 2023: $8,702 · 2024: $6,920 · 2025: $7,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Consulting Fee: $2,400 · Travel and Lodging: $1,275 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,965.01 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $1,274.78 |
| Education | $114.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $7,372.01 | 2019-2025 | Mavenclad, Mavenclad |
| Livanova USA, INC. | $2,680.95 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $2,518.87 | 2019-2025 | |
| Abbvie INC. | $1,839.81 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $1,122.08 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Biogen, INC. | $942.39 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Neurocrine Biosciences, INC. | $769.98 | 2019-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $746.16 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $703.31 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Sk Life Science, INC. | $685.22 | 2021-2025 | |
| Celgene Corporation | $684.36 | 2023-2025 | Zeposia |
| Ani Pharmaceuticals, INC. | $673.13 | 2022-2025 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $667.47 | 2019-2025 | Qelbree |
| Pfizer INC. | $600.46 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $529.78 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $527.81 | 2019-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $459.65 | 2019-2025 | Vyepti, Rexulti |
| Kyowa Kirin, INC. | $427.36 | 2021-2025 | Nourianz |
| Eisai INC. | $388.53 | 2019-2025 | |
| Tg Therapeutics, INC. | $351.49 | 2024-2025 | |
| Argenx US, INC. | $322.48 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $321.74 | 2019-2025 | Lyvispah, Rytary, Crexont |
| Alexion Pharmaceuticals, INC. | $295.02 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $276.68 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $273.07 | 2021-2022 | |
| Banner Life Sciences, LLC | $247.80 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $235.84 | 2023-2025 | Nuedexta, Rexulti |
| Allergan, INC. | $234.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.46 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $230.10 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $224.68 | 2019-2025 | Nuplazid, Daybue |
| Csl Behring | $222.46 | 2022-2025 | Hizentra |
| Mallinckrodt Hospital Products INC. | $205.67 | 2022-2024 | Acthar |
| Adamas Pharmaceuticals, INC. | $172.96 | 2019-2020 | |
| Mdd US Operations, LLC | $172.16 | 2020-2025 | Apokyn, Apokyn |
| Sumitomo Pharma America, INC. | $167.48 | 2023 | Aptiom |
| Currax Pharmaceuticals LLC | $156.55 | 2020-2024 | Onzetra Xsail |
| Avanir Pharmaceuticals, INC. | $155.35 | 2019-2022 | |
| Axsome Therapeutics, INC. | $153.01 | 2023-2025 | Sunosi, Symbravo |
| Acorda Therapeutics, INC | $149.50 | 2019-2024 | Inbrija, Ampyra |
| Biohaven Pharmaceuticals, INC. | $132.57 | 2021 | |
| Merz Pharmaceuticals, LLC | $119.24 | 2022-2025 | Xeomin, Inbrija |
| Novo Nordisk INC | $110.25 | 2020 | |
| Vanda Pharmaceuticals INC. | $109.04 | 2025 | Ponvory |
| Jazz Pharmaceuticals INC. | $102.78 | 2021-2025 | |
| Genentech, INC. | $96.99 | 2023 | Ocrevus, Enspryng |
| Takeda Pharmaceuticals U.S.A., INC. | $94.86 | 2024-2025 | Hyqvia |
| Ge Healthcare | $91.03 | 2023-2024 | |
| Abbott Laboratories | $87.09 | 2022-2024 | Infinity |
| Horizon Therapeutics Plc | $73.44 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $63.72 | 2023 | Onpattro |
| Avion Pharmaceuticals | $59.02 | 2022-2023 | Dhivy |
| Merz North America, INC. | $47.25 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.09 | 2022 | |
| Scilex Pharmaceuticals INC. | $34.30 | 2023-2024 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $30.81 | 2022 | |
| Kedrion Biopharma, INC. | $27.34 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Gammaked |
| Bio Products Laboratory USA, INC. | $26.93 | 2023 | Gammaplex, Coagadex |
| Tanabe Pharma America, INC. | $21.92 | 2023 | |
| Cycle Pharmaceuticals INC | $20.52 | 2025 | Tascenso Odt, Bafiertam |
| Azurity Pharmaceuticals, INC. | $20.09 | 2024 | Horizant |
| Mallinckrodt Enterprises LLC | $19.82 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $19.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.08 | 2022 | |
| Grifols USA, LLC | $17.71 | 2025 | Gamunex-C |
| Neurelis, INC. | $17.63 | 2025 | Valtoco |
| Life Molecular Imaging LTD | $15.17 | 2025 | Neuraceq |
| Vertical Pharmaceuticals, LLC | $14.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.72 | 2022 | |
| Zyla Life Sciences, INC. | $12.94 | 2019 | |
| Promius Pharma LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.